Document Detail


ADP mediates inhibition of insulin secretion by activation of P2Y13 receptors in mice.
MedLine Citation:
PMID:  20526761     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS/HYPOTHESES: To investigate the effects of extracellular purines on insulin secretion from mouse pancreatic islets. METHODS: Mouse islets and beta cells were isolated and examined with mRNA real-time quantification, cAMP quantification and insulin and glucagon secretion. ATP release was measured in MIN6c4 cells. Insulin and glucagon secretion were measured in vivo after glucose injection. RESULTS: Enzymatic removal of extracellular ATP at low glucose levels increased the secretion of both insulin and glucagon, while at high glucose levels insulin secretion was reduced and glucagon secretion was stimulated, indicating an autocrine effect of purines. In MIN6c4 cells it was shown that glucose does induce release of ATP into the extracellular space. Quantitative real-time PCR demonstrated the expression of the ADP receptors P2Y(1) and P2Y(13) in both intact mouse pancreatic islets and isolated beta cells. The stable ADP analogue 2-MeSADP had no effect on insulin secretion. However, co-incubation with the P2Y(1) antagonist MRS2179 inhibited insulin secretion, while co-incubation with the P2Y(13) antagonist MRS2211 stimulated insulin secretion, indicating that ADP acting via P2Y(1) stimulates insulin secretion, while signalling via P2Y(13) inhibits the secretion of insulin. P2Y(13) antagonism through MRS2211 per se increased the secretion of both insulin and glucagon at intermediate (8.3 mmol/l) and high (20 mmol/l) glucose levels, confirming an autocrine role for ADP. Administration of MRS2211 during glucose injection in vivo resulted in both increased secretion of insulin and reduced glucose levels. CONCLUSIONS/INTERPRETATION: In conclusion, ADP acting on the P2Y(13) receptors inhibits insulin release. An antagonist to P2Y(13) increases insulin release and could be evaluated for the treatment of diabetes.
Authors:
S Amisten; S Meidute-Abaraviciene; C Tan; B Olde; I Lundquist; A Salehi; D Erlinge
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-06
Journal Detail:
Title:  Diabetologia     Volume:  53     ISSN:  1432-0428     ISO Abbreviation:  Diabetologia     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-07-28     Completed Date:  2010-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0006777     Medline TA:  Diabetologia     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1927-34     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Lund University, Skane University Hospital, Lund, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine Diphosphate / analogs & derivatives,  metabolism*,  pharmacology
Adenosine Triphosphate / metabolism
Animals
Apyrase / metabolism
Cell Line
Cells, Cultured
Cyclic AMP / metabolism
Female
Glucagon / metabolism
Insulin / secretion*
Insulin-Secreting Cells / drug effects,  metabolism
Islets of Langerhans / drug effects,  metabolism
Mice
Polymerase Chain Reaction
Receptors, Purinergic P2 / metabolism*
Thionucleotides / pharmacology
Chemical
Reg. No./Substance:
0/2-methylthio-ADP; 0/P2ry13 protein, mouse; 0/Receptors, Purinergic P2; 0/Thionucleotides; 0/purinoceptor P2Y1; 11061-68-0/Insulin; 56-65-5/Adenosine Triphosphate; 58-64-0/Adenosine Diphosphate; 60-92-4/Cyclic AMP; 9007-92-5/Glucagon; EC 3.6.1.5/Apyrase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in a...
Next Document:  Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in peop...